Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age

Haruko Shima, Masashi Miharu, Tomoo Osumi, Takao Takahashi, Hiroyuki Shimada

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The relationship between trough plasma concentrations and daily doses of voriconazole was retrospectively analyzed in ≤18-year-old children because optimal oral voriconazole dosages for children, especially <2 years of age, is unknown. We demonstrated that the relationship changed around the age of 3 years, and that children <3 years of age required higher optimal daily doses with greater variations compared with those for older children, resulting in complicated optimal dose adjustments. Therefore, plasma concentration monitoring and individual dose adjustments are recommended for optimal and less toxic voriconazole treatments, especially for <3-year-old children, although additional studies are needed to validate this approach.

Original languageEnglish
Pages (from-to)1050-1052
Number of pages3
JournalPediatric Blood and Cancer
Volume54
Issue number7
DOIs
Publication statusPublished - 2010 Jul 1

Fingerprint

Poisons
Voriconazole
Therapeutics

Keywords

  • Fungal infection
  • Plasma monitoring
  • Voriconazole

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

@article{b3e4916211a745b2bfbe6a1a9ffd8c46,
title = "Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age",
abstract = "The relationship between trough plasma concentrations and daily doses of voriconazole was retrospectively analyzed in ≤18-year-old children because optimal oral voriconazole dosages for children, especially <2 years of age, is unknown. We demonstrated that the relationship changed around the age of 3 years, and that children <3 years of age required higher optimal daily doses with greater variations compared with those for older children, resulting in complicated optimal dose adjustments. Therefore, plasma concentration monitoring and individual dose adjustments are recommended for optimal and less toxic voriconazole treatments, especially for <3-year-old children, although additional studies are needed to validate this approach.",
keywords = "Fungal infection, Plasma monitoring, Voriconazole",
author = "Haruko Shima and Masashi Miharu and Tomoo Osumi and Takao Takahashi and Hiroyuki Shimada",
year = "2010",
month = "7",
day = "1",
doi = "10.1002/pbc.22451",
language = "English",
volume = "54",
pages = "1050--1052",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age

AU - Shima, Haruko

AU - Miharu, Masashi

AU - Osumi, Tomoo

AU - Takahashi, Takao

AU - Shimada, Hiroyuki

PY - 2010/7/1

Y1 - 2010/7/1

N2 - The relationship between trough plasma concentrations and daily doses of voriconazole was retrospectively analyzed in ≤18-year-old children because optimal oral voriconazole dosages for children, especially <2 years of age, is unknown. We demonstrated that the relationship changed around the age of 3 years, and that children <3 years of age required higher optimal daily doses with greater variations compared with those for older children, resulting in complicated optimal dose adjustments. Therefore, plasma concentration monitoring and individual dose adjustments are recommended for optimal and less toxic voriconazole treatments, especially for <3-year-old children, although additional studies are needed to validate this approach.

AB - The relationship between trough plasma concentrations and daily doses of voriconazole was retrospectively analyzed in ≤18-year-old children because optimal oral voriconazole dosages for children, especially <2 years of age, is unknown. We demonstrated that the relationship changed around the age of 3 years, and that children <3 years of age required higher optimal daily doses with greater variations compared with those for older children, resulting in complicated optimal dose adjustments. Therefore, plasma concentration monitoring and individual dose adjustments are recommended for optimal and less toxic voriconazole treatments, especially for <3-year-old children, although additional studies are needed to validate this approach.

KW - Fungal infection

KW - Plasma monitoring

KW - Voriconazole

UR - http://www.scopus.com/inward/record.url?scp=77951723812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951723812&partnerID=8YFLogxK

U2 - 10.1002/pbc.22451

DO - 10.1002/pbc.22451

M3 - Article

VL - 54

SP - 1050

EP - 1052

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -